The company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug
The guidance also urges companies to act quickly to initiate a recall when public health is at risk and to do so prior to completing an investigation into the cause of the problem
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
It plans launch various other health monitoring tools for smartphones, making existing devices obsolete
A total of 17 labs will be operational across the country by this month
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
The accelerated growth of Medix Biochemica will establish its status as the ultimate IVD raw materials supplier
Subscribe To Our Newsletter & Stay Updated
